PDF(Pubmed)
Abstract：
Shigellosis is a severe gastrointestinal disease that annually affects approximately 270 million individuals globally. It has particularly high morbidity and mortality in low-income regions; however, it is not confined to these regions and occurs in high-income nations when conditions allow. The ill effects of shigellosis are at their highest in children ages 2 to 5, with survivors often exhibiting impaired growth due to infection-induced malnutrition. The escalating threat of antibiotic resistance further amplifies shigellosis as a serious public health concern. This review explores Shigella pathology, with a primary focus on the status of Shigella vaccine candidates. These candidates include killed whole-cells, live attenuated organisms, LPS-based, and subunit vaccines. The strengths and weaknesses of each vaccination strategy are considered. The discussion includes potential Shigella immunogens, such as LPS, conserved T3SS proteins, outer membrane proteins, diverse animal models used in Shigella vaccine research, and innovative vaccine development approaches. Additionally, this review addresses ongoing challenges that necessitate action toward advancing effective Shigella prevention and control measures.
摘要：
志贺氏菌病是一种严重的胃肠道疾病，每年影响全球约2.7亿人。在低收入地区，发病率和死亡率特别高；然而，它不仅限于这些地区，而且在条件允许的情况下发生在高收入国家。志贺氏菌病的不良影响在2至5岁的儿童中最高，幸存者通常由于感染引起的营养不良而表现出生长受损。不断升级的抗生素耐药性威胁进一步扩大了志贺氏菌病，成为严重的公共卫生问题。这篇综述探讨了志贺氏菌的病理学，主要关注志贺氏菌候选疫苗的状况。这些候选者包括杀死的全细胞,活的减毒生物，基于LPS，和亚单位疫苗。考虑了每种疫苗接种策略的优缺点。讨论包括潜在的志贺氏菌免疫原，如LPS，保守的T3SS蛋白，外膜蛋白，志贺氏菌疫苗研究中使用的不同动物模型，和创新的疫苗开发方法。此外,本综述解决了持续存在的挑战,这些挑战需要采取行动来推进有效的志贺氏菌预防和控制措施.
